The intramuscular injection nobody intended
Longer needles reach muscle in lean limbs, and intramuscular delivery of a long-acting depot changes absorption in ways nobody wants.
Archive — 2025
Volume II: 12 issues, 2,040 pieces.
The online reseller trading as Adamant Research Supply enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Australia caps exenatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
TRIUMPH-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A reference interval is not a target, and a result outside one is not a diagnosis
Almost every misreading of a laboratory panel is a misunderstanding of what a reference interval is and how much a result has to move before the movement means anything.
We split six vials four ways and posted them
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
From the floor in Chengdu: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Australia declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Hong Kong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
A supplier suspends shipping to Germany after 20 consecutive customs detentions
The route did not close because of a rule about peptides.
What actually helps, ranked by evidence
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
What we asked twenty suppliers about stability data
What would make a difference is not a regulator. It is three lines on a certificate, all of which are already known to whoever wrote it.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 26% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A mass on a WWB certificate is a beginning, not a conclusion
What a single-stage mass measurement supports, what it excludes, and the gap between the two.
The escalation table is the thinnest page in the label
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
Independent analysis puts a GL Biochem liraglutide lot at 97.5%, against 93.6% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
QYB declines, for the 17th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Tandem mass spectrometry, and the difference between weighing and reading
An intact mass measurement establishes elemental composition, at best. The number of distinct sequences consistent with a given composition is astronomically large.
The badge is about a sample. The listing is about a product.
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Two decimal places, one injection, no procedure
This piece takes the measurement apart into the decisions it is made of, because each decision moves the answer.
Medutest result on a Tianjin exenatide lot lands 2.1 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
What a 23% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
Mexico pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The one randomised trial that combined an incretin with supervised exercise
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.